Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. 2005;13(4):219–27.

Google Scholar 

Zhou H, Zhao Y, Zhang M, Yao J, Leng S, Li X, et al. Randomized, phase III trial of mixed formulation of fosrolapitant and palonosetron (HR20013) in preventing cisplatin-based highly emetogenic chemotherapy-induced nausea and vomiting: PROFIT. J Clin Oncol. 2025;43(9):1123–36.

Article  CAS  PubMed  Google Scholar 

Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015;26(6):1081–90.

Article  CAS  PubMed  Google Scholar 

Belluomini L, Avancini A, Sposito M, Pontolillo L, Tregnago D, Trestini I, et al. Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: the road to success. Crit Rev Oncol Hematol. 2024;201:104444, 104444. https://doi.org/10.1016/j.critrevonc.2024.104444.

Kennedy SKF, Goodall S, Lee SF, DeAngelis C, Jocko A, Charbonneau F, et al. 2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 2020;32(5):280, 280. https://doi.org/10.1007/s00520-024-08462-x.

Jordan K, de Azambuja E, García Del Barrio M, Jahn F, Di Palma M, Scotté F, et al. Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. Eur J Cancer. 2025;222:115451.

Article  CAS  PubMed  Google Scholar 

Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2023;9(2):102195. https://doi.org/10.1016/j.esmoop.2023.102195.

Article  Google Scholar 

Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020;31(11):1553–60.

Article  CAS  PubMed  Google Scholar 

Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. J Oncol Pract. 2014;10(1):68–74.

Article  PubMed  Google Scholar 

Molassiotis A, Jordan K, Karthaus M, Dranitsaris G, Roeland EJ, Schwartzberg L, et al. Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial. Ann Oncol. 2025. https://doi.org/10.1016/j.annonc.2025.10.017.

Article  PubMed  Google Scholar 

Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018;29(2):452–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeo W, Ngai NTY, Yip CCH, Mo FKF, Yeo VA, Ko JWH, et al. Risk factors associated with chemotherapy-induced nausea and vomiting among women with breast cancer receiving highly emetogenic chemotherapy: individual patient-based analysis of three prospective antiemetic trials. Cancer Manag Res. 2024;16:283–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scotté F. Identifying predictive factors of chemotherapy-induced nausea and vomiting (CINV): a novel approach. Ann Oncol. 2017;28(6):1165–7.

Article  PubMed  Google Scholar 

Shih V, Wan HS, Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother. 2009;43(3):444–52.

Article  PubMed  Google Scholar 

Grassi L, Berardi MA, Ruffilli F, Meggiolaro E, Andritsch E, Sirgo A, et al. Role of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: a European study. Psychother Psychosom. 2015;84(6):339–47.

Article  PubMed  Google Scholar 

Di Mattei VE, Carnelli L, Carrara L, Bernardi M, Crespi G, Rancoita PMV, et al. Chemotherapy-induced nausea and vomiting in women with gynecological cancer: a preliminary single-center study investigating medical and psychosocial risk factors. Cancer Nurs. 2016;39(6):E52–9.

Article  PubMed  Google Scholar 

Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer. 2002;10(2):139–45.

CAS  PubMed  Google Scholar 

Navari RM. Cancer patients at high risk for chemotherapy-induced nausea and vomiting – prediction assessments/tools. Expert Rev Qual Life Cancer Care. 2017;2(2):103–8.

Google Scholar 

Molassiotis A, Lee PH, Burke TA, Dicato M, Gascon P, Roila F, et al. Anticipatory nausea, risk factors, and its impact on chemotherapy-induced nausea and vomiting: results from the Pan European Emesis Registry Study. J Pain Symptom Manage. 2016;51(6):987–93.

Article  PubMed  Google Scholar 

Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822–30.

Article  CAS  PubMed  Google Scholar 

Higgins SC, Montgomery GH, Bovbjerg DH. Distress before chemotherapy predicts delayed but not acute nausea. Support Care Cancer. 2007;15(2):171–7.

PubMed  Google Scholar 

Lazarus RS, Folkman S. Stress, appraisal, and coping. Springer Publishing Company; 1984.

Wolf BM, Fisher CL. Stress, appraisal, and coping theory. In: The international encyclopedia of health communication. 2022. p. 1–6.

Google Scholar 

Donovan KA, Handzo G, Corbett C, Vanderlan J, Brewer BW, Ahmed K. NCCN distress thermometer problem list update. J Natl Compr Canc Netw. 2022;20(1):96–8.

Article  PubMed  Google Scholar 

Zhu C, Chen Q, Du W, Xu H, He X. Evaluating psychological distress in Chinese patients with head and neck squamous cell carcinoma planned for radiotherapy: a cross-sectional study using the distress thermometer. BMC Psychol. 2024;12(1):577. https://doi.org/10.1186/s40359-024-02081-1.

Article  PubMed  PubMed Central  Google Scholar 

Greer S, Watson M. Mental adjustment to cancer: its measurement and prognostic importance. Cancer Surv. 1987;6(3):439–53.

CAS  PubMed  Google Scholar 

Ho SM, Fung WK, Chan CL, Watson M, Tsui YK. Psychometric properties of the Chinese version of the Mini-Mental Adjustment to Cancer (MINI-MAC) scale. Psychooncology. 2003;12(6):547–56.

Article  PubMed  Google Scholar 

Mosa ASM, Hossain AM, Lavoie BJ, Yoo I. Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol. 2020;11:329. https://doi.org/10.3389/fphar.2020.00329.

Article  PubMed  PubMed Central  Google Scholar 

Warr D. Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol. 2014;722:192–6.

Article  CAS  PubMed  Google Scholar 

Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage. 2014;47(5):839-48.e4.

Article  PubMed  Google Scholar 

Scotté F, Schwartzberg L, Iihara H, Aapro M, Gralla R, Hesketh PJ, et al. 2023 updated MASCC/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer. 2023;32(1):45. https://doi.org/10.1007/s00520-023-08222-3.

Article  PubMed  Google Scholar 

Tan JY, Suen LK, Molassiotis A. Psychometric assessment of the Chinese version of the MASCC Antiemesis Tool (MAT) for measuring chemotherapy-induced nausea and vomiting. Support Care Cancer. 2016;24(9):3729–37.

PubMed  Google Scholar 

Sun Y, Zheng Y, Yang X, Xie K, Du C, He L, et al. Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan. China J Cancer Res Clin Oncol. 2021;147(9):2701–8.

CAS  PubMed  PubMed Central  Google Scholar 

Chow R, Yin LB, Baqri W, Huang R, Boldt G, Younus J, et al. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis. Support Care Cancer. 2023;31(8):505. https://doi.org/10.1007/s00520-023-07978-y

Article  PubMed  Google Scholar 

Dufner V, Kessler AF, Just L, Hau P, Bumes E, Pels HJ, et al. The Emesis trial: depressive glioma patients are more affected by chemotherapy-induced nausea and vomiting. Front Neurol. 2022;13:773265, 773265. https://doi.org/10.3389/fneur.2022.773265.

Peng S, Xiao F, Chen M, Gao H. Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci (Weinh). 2022;9(1):e2103836.

Article